TNSN98200A1 - Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol leur preparation et composition pharmaceutique les contenant - Google Patents

Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol leur preparation et composition pharmaceutique les contenant

Info

Publication number
TNSN98200A1
TNSN98200A1 TNTNSN98200A TNSN98200A TNSN98200A1 TN SN98200 A1 TNSN98200 A1 TN SN98200A1 TN TNSN98200 A TNTNSN98200 A TN TNSN98200A TN SN98200 A TNSN98200 A TN SN98200A TN SN98200 A1 TNSN98200 A1 TN SN98200A1
Authority
TN
Tunisia
Prior art keywords
activity
compounds
preparation
therapeutically active
catechol
Prior art date
Application number
TNTNSN98200A
Other languages
English (en)
Inventor
Marfat Anthony
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN98200A1 publication Critical patent/TNSN98200A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

L'INVENTION CONCERNE DES COMPOSITIONS DE MATIERE THERAPEUTIQUEMENT ACTIVES COMPRENANT DES COMPOSES INDAZOLIQUES, CES COMPOSES ET LEUR ACTIVITE THERAPEUTIQUE RESULTANT DIRECTEMENT D'UN REMPLACEMENT BIO-ISOSTERIQUE DU CATECHOL PAR L'INDAZOLE DANS UN COMPOSE CONTENANT DU CATECHOL AYANT LA MEME ACTIVITE THERAPEUTIQUE, LES SUBSTITUANTS NON-CATECHOLS ETANT LES MEMES OU ETANT HOMOLOGUES AVANT ET APRES LE REMPLACEMENT, CES COMPOSES REPONDANT A LA FORMULE (I1) OU (12). OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CES COMPOSES. L'INVENTION CONCERNE EGALEMENT LA PREPARATION DE CES COMPOSES ET DES PREPARATIONS PHARMACEUTIQUES QUI LES CONTIENNENT. L'ACTIVITE THERAPEUTIQUE MISE EN JEU PEUT COMPRENDRE UNE ACTIVITE INHIBITRICE DE CHOLINESTERASE, UNE ACTIVITE α1-ANTAGONISTE ET β1 -AGONISTE ADRENERGIQUE, UNE ACTIVITE INHIBITRICE DES CANAUX Ca2+, UNE ACTIVITE ANTI-NEOPLASIQUE ET UNE ACTIVITE INHIBITRICE DE PHOSPHODIESTERASE DU TYPE IV,
TNTNSN98200A 1997-11-04 1998-11-03 Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol leur preparation et composition pharmaceutique les contenant TNSN98200A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6419897P 1997-11-04 1997-11-04
US6418797P 1997-11-04 1997-11-04
US6422997P 1997-11-04 1997-11-04
US6422897P 1997-11-04 1997-11-04
US6402497P 1997-11-04 1997-11-04

Publications (1)

Publication Number Publication Date
TNSN98200A1 true TNSN98200A1 (fr) 2005-03-15

Family

ID=27535645

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98200A TNSN98200A1 (fr) 1997-11-04 1998-11-03 Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol leur preparation et composition pharmaceutique les contenant

Country Status (29)

Country Link
US (1) US6391872B1 (fr)
EP (1) EP1028946A1 (fr)
JP (1) JP2001521926A (fr)
CN (1) CN1284948A (fr)
AP (1) AP910A (fr)
AR (1) AR013746A1 (fr)
AU (1) AU754734B2 (fr)
BG (1) BG104450A (fr)
BR (1) BR9813926A (fr)
CA (1) CA2309150A1 (fr)
CZ (1) CZ20001621A3 (fr)
DZ (1) DZ2640A1 (fr)
EA (1) EA200000488A1 (fr)
HR (1) HRP20000253A2 (fr)
HU (1) HUP0004150A3 (fr)
ID (1) ID23921A (fr)
IL (1) IL135900A0 (fr)
IS (1) IS5465A (fr)
MA (1) MA26563A1 (fr)
NO (1) NO20002129L (fr)
NZ (1) NZ503918A (fr)
OA (1) OA11354A (fr)
PE (1) PE129199A1 (fr)
PL (1) PL340753A1 (fr)
SK (1) SK6252000A3 (fr)
TN (1) TNSN98200A1 (fr)
TR (1) TR200001234T2 (fr)
WO (1) WO1999023077A1 (fr)
YU (1) YU25000A (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2309175A1 (fr) * 1997-11-04 1999-05-14 Pfizer Products Inc. Composes therapeutiquement actifs obtenus par remplacement du catechol par un bio-isostere d'indazole dans des inhibiteurs de pde4
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
JP2001031549A (ja) * 1999-07-14 2001-02-06 Pola Chem Ind Inc 真皮コラーゲン線維束再構築剤及びそれを含有する化粧料
KR20020018201A (ko) * 1999-08-12 2002-03-07 윌리암 에이취 캘넌, 에곤 이 버그 결장 폴립 및 결장직장암의 치료 또는 억제용엔에스에이아이디 및 이지에프알 키나제 억제제 함유 조성물
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US7005443B1 (en) * 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
WO2001079198A1 (fr) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases
DE60234510D1 (de) 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1h-indazolverbindungen die jnk hemmen
US20040242597A1 (en) 2001-09-19 2004-12-02 Thomas Klein Combination
WO2003024456A1 (fr) * 2001-09-20 2003-03-27 Eisai Co., Ltd. Methodes de traitement et de prevention des migraines
KR20040085179A (ko) * 2002-02-13 2004-10-07 코닌클리케 필립스 일렉트로닉스 엔.브이. 통합된 반도체 광학 디바이스, 이러한 디바이스를제조하는 방법 및 장치
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US7514469B2 (en) 2002-04-30 2009-04-07 Unigen Pharmaceuticals, Inc. Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
US8034387B2 (en) 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
BR0316950A (pt) 2002-12-02 2006-01-17 Hoffmann La Roche Derivados de indazol como antagonistas de crf
WO2004074243A2 (fr) * 2003-02-14 2004-09-02 Wyeth Heterocyclyl-3-sulfonylindazoles utilises comme ligands de la 5-hydroxytryptamine-6
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2521429A1 (fr) * 2003-04-04 2004-10-21 Unigen Pharmaceuticals, Inc. Formulation destinee a inhiber la cyclooxygenase (cox) et la lipoxygenase (lox) utilisee dans les soins cutanes
US6984652B2 (en) 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
KR100843526B1 (ko) 2004-02-27 2008-07-03 에프. 호프만-라 로슈 아게 피라졸의 접합 유도체
WO2005085248A1 (fr) 2004-02-27 2005-09-15 F.Hoffmann-La Roche Ag Derives pyrazolo heteroaryl-condenses
EP1747202A1 (fr) 2004-02-27 2007-01-31 F.Hoffmann-La Roche Ag Derives d'indazole et compositions pharmaceutiques renfermant ceux-ci
US7844309B2 (en) * 2004-02-27 2010-11-30 Nokia Corporation Exchangeable keymat
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
JP4130219B2 (ja) * 2004-11-29 2008-08-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 治療用のピラゾロ［３，４−ｂ］ピリジンおよびインダゾール
MX2008002158A (es) * 2005-08-15 2008-04-19 Wyeth Corp Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
RU2429231C2 (ru) * 2005-08-15 2011-09-20 Вайет Производные замещенного-3-сульфонилиндазола в качестве лигандов 5-гидрокситриптамина-6
CN101243088B (zh) 2005-08-25 2011-06-29 霍夫曼-拉罗奇有限公司 p38 MAP激酶抑制剂及使用它的方法
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
CA2628413C (fr) * 2005-11-03 2014-09-23 Allergan, Inc. Prostaglandines et analogues utilises en tant qu'agents pour abaisser la pression intraoculaire
RU2008127501A (ru) 2006-01-13 2010-02-20 Вайет (Us) Сульфонилзамещенные 1н-индолы в качастве лигандов 5-гидрокситриптаминовых рецепторов
JP5131990B2 (ja) 2006-01-31 2013-01-30 アレイ バイオファーマ、インコーポレイテッド キナーゼ阻害剤およびその使用方法
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
WO2007120523A2 (fr) * 2006-03-31 2007-10-25 Vitae Pharmaceuticals, Inc. 6-(aminoalkyl)indazoles
WO2007117413A1 (fr) * 2006-04-05 2007-10-18 Wyeth Dérivés de sulfonyl-3-hétérocyclylindazole utilisés en tant que ligands de la 5-hydroxytryptamine-6
WO2007120596A1 (fr) * 2006-04-12 2007-10-25 Wyeth DÉRIVÉS DE DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
US8012886B2 (en) * 2007-03-07 2011-09-06 Asm Assembly Materials Ltd Leadframe treatment for enhancing adhesion of encapsulant thereto
EP2124944B1 (fr) 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Dérivés de pyrazolo[3,4-b]pyridine comme inhibiteurs de phosphodiestérase
US8558016B2 (en) * 2009-09-18 2013-10-15 Kabaushiki Kaisha Riverson Polyphenol derivative and method for producing the same
EP2569301A1 (fr) 2010-05-12 2013-03-20 Abbvie Inc. Inhibiteurs indazoliques des kinases
CN103709146B (zh) * 2014-01-15 2015-11-25 中国药科大学 一类含苯并咪唑结构的喹啉-4-胺衍生物、其制法及医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338087A4 (en) * 1987-10-13 1991-07-24 Yoshitomi Pharmaceutical Industries, Ltd. Fused pyrazole compounds, process for their preparation, and their medicinal use
WO1989003385A1 (fr) * 1987-10-13 1989-04-20 Yoshitomi Pharmaceutical Industries, Ltd. Composes de pyrazole fusionnes, procede de preparation et utilisation en medecine
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
KR100338610B1 (ko) * 1996-09-04 2002-05-27 디. 제이. 우드, 스피겔 알렌 제이 인다졸 유도체 및 포스포디에스터라제 (pde) 유형 iv 및 종양괴사인자 (tnf) 생산의 억제제로서 그의 용도

Also Published As

Publication number Publication date
CA2309150A1 (fr) 1999-05-14
NO20002129L (no) 2000-07-03
PL340753A1 (en) 2001-02-26
HRP20000253A2 (en) 2001-06-30
CN1284948A (zh) 2001-02-21
ID23921A (id) 2000-05-25
DZ2640A1 (fr) 2003-03-08
EP1028946A1 (fr) 2000-08-23
AU754734B2 (en) 2002-11-21
BR9813926A (pt) 2000-09-19
CZ20001621A3 (cs) 2001-08-15
HUP0004150A3 (en) 2001-08-28
OA11354A (en) 2003-12-23
AP9801375A0 (en) 1998-12-31
SK6252000A3 (en) 2001-11-06
WO1999023077A1 (fr) 1999-05-14
NZ503918A (en) 2002-03-28
PE129199A1 (es) 1999-12-16
AP910A (en) 2000-12-05
YU25000A (sh) 2003-12-31
TR200001234T2 (tr) 2000-08-21
MA26563A1 (fr) 2004-12-20
JP2001521926A (ja) 2001-11-13
IS5465A (is) 2000-04-19
HUP0004150A2 (hu) 2001-05-28
AU9455298A (en) 1999-05-24
EA200000488A1 (ru) 2000-10-30
AR013746A1 (es) 2001-01-10
IL135900A0 (en) 2001-05-20
US6391872B1 (en) 2002-05-21
NO20002129D0 (no) 2000-04-26
BG104450A (en) 2000-12-29

Similar Documents

Publication Publication Date Title
TNSN98200A1 (fr) Composes therapeutiquement actifs contenant de l'indazole en remplacement bio-isosterique du catechol leur preparation et composition pharmaceutique les contenant
EP0954299B1 (fr) Analogues de thyroxine depourvus d'activite hormonale pour le traitement de tumeurs malignes
Yamada et al. Brain dysfunction associated with an induction of nitric oxide synthase following an intracerebral injection of lipopolysaccharide in rats
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
DE69930619T2 (de) Verwendung von rosmarinsäure und deren derivate als immunsuppressor oder als inhibitor von sh-2 vermittelten prozessen
TNSN98199A1 (fr) Composes therapeutiquement actifs bases sur le remplacement bio- isosterique du catechol par l'indazole dans des inhibiteurs de pde4, leur procede de production et composition pharmaceutique les contenant
JP3887020B2 (ja) アズレニルニトロンスピントラッピング剤、ならびにその製造方法および使用方法
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
TNSN99142A1 (fr) Derives de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procede pour leur preparation.
TNSN97110A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant
RU94043809A (ru) Лекарственная композиция для релизконтроля
TNSN98150A1 (fr) Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
HUP0000838A2 (hu) Szteroid-glikozidot tartalmazó extraktum, eljárás izolálására és szintetikus előállítására, valamint ezt tartalmazó étvágycsökkentő gyógyszerkészítmények
WO1997046228A9 (fr) Procede de traitement de tumeurs malignes avec des analogues de thyroxine n'ayant pas d'activite hormonale importante
BR0212787A (pt) Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica
WO2001093841A3 (fr) Analogues de l'acide barbiturique utilises comme agents therapeutiques
Wu et al. L-α-aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: a microdialysis study in freely moving rats
FR2703249B1 (fr) Composition pharmaceutique ayant une activité analgésique contenant du naproxène.
DE59610175D1 (de) Hydantoinderivate als zwischenprodukte für pharmazeutische wirkstoffe
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
US20030171379A1 (en) Methods of treating, preventing, or inhibiting inflammation with Mactanamide compounds
US20150164837A1 (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
SK117794A3 (en) Enatiomeric 1-phenyl-2-(2-pyridinyl)ethylamene for the treatment of neurogenerative disorders